Related Experiment Video
Updated: Apr 7, 2026

3-D Imaging and Analysis of Neurons Infected In Vivo with Toxoplasma gondii
Published on: December 9, 2014
MIC3, a novel cross-protective antigen expressed in Toxoplasma gondii and Neospora caninum
Daoyu Yang1, Jing Liu, Pan Hao
1Key Laboratory of Animal Epidemiology and Zoonosis, Ministry of Agriculture, Beijing, China.
Abstract:
Microneme protein 3 (MIC3) is an important adhesion molecule expressed by Toxoplasma gondii and Neospora caninum that plays a crucial role in invasion. In our study, we found that recombinant TgMIC3 (rTgMIC3) was recognized by both T. gondii-reactive sera and hyper-immune serum against N. caninum. Polyclonal antibodies against TgMIC3 reacted with N. caninum by western blot and immunofluorescence assay (IFA). These results indicate that MIC3 is a novel cross-reactive antigen expressed in N. caninum and T. gondii. To evaluate the immune-protective effect of TgMIC3, we created the eukaryotic expression vector pcDNA3.1-TgMIC3, transfected this vector into HEK293T cells by lipofection, and evaluated TgMIC3 expression in HEK293T cells using western blot and IFA. Then, groups of BALB/c mice were immunized with recombinant TgMIC3 protein, pcDNA3.1-TgMIC3, or two-vaccine immunization. The mice were challenged with T. gondii RH or N. caninum Nc-1 tachyzoites 14 days after the final immunization. The survival time of T. gondii-infected mice was recorded, and the parasite burden in the brain of N. caninum-infected mice 30 days post-infection was measured using real-time PCR. The results demonstrated that mice immunized with TgMIC3-based vaccines elicited high antibody titers. After parasitic challenge, mice immunized with pcDNA-TgMIC3 exhibited prolonged survival when infected with T. gondii tachyzoites and a lower parasitic burden in the brains of mice challenged with N. caninum tachyzoites. These results demonstrate that TgMIC3 is a cross-protective antigen expressed in T. gondii and N. caninum and could elicit some protection against toxoplasmosis and neosporosis.
Insights
Toxoplasma gondii microneme protein 3 (MIC3) acts as a cross-protective antigen against both toxoplasmosis and neosporosis. Vaccination with MIC3-based strategies improved survival and reduced parasite burden in mice challenged with T. gondii and N. caninum.
Area of Science:
- Immunology
- Parasitology
- Molecular Biology
Background:
- Microneme protein 3 (MIC3) is vital for invasion by *Toxoplasma gondii* and *Neospora caninum*.
- Previous studies identified MIC3 as a key adhesion molecule in these parasites.
Purpose of the Study:
- To investigate MIC3 as a cross-reactive antigen between *T. gondii* and *N. caninum*.
- To evaluate the immune-protective potential of *T. gondii* MIC3 (TgMIC3) as a vaccine candidate against both parasitic infections.
Main Methods:
- Recombinant TgMIC3 (rTgMIC3) was generated and tested against *T. gondii* and *N. caninum* reactive sera.
- Polyclonal antibodies against TgMIC3 were used for western blot and immunofluorescence assays (IFA).
- Mice were immunized with rTgMIC3, a pcDNA3.1-TgMIC3 expression vector, or a combination, then challenged with *T. gondii* or *N. caninum* tachyzoites.
Main Results:
- TgMIC3 was recognized by sera from both *T. gondii* and *N. caninum*-infected individuals, confirming cross-reactivity.
- Immunization with TgMIC3-based vaccines induced high antibody titers.
- Mice vaccinated with the pcDNA3.1-TgMIC3 vector showed prolonged survival against *T. gondii* challenge and reduced *N. caninum* brain parasite burden.
Conclusions:
- TgMIC3 is a novel cross-reactive antigen shared by *T. gondii* and *N. caninum*.
- TgMIC3-based vaccination strategies demonstrate cross-protective immunity against toxoplasmosis and neosporosis.
- TgMIC3 holds potential as a subunit vaccine candidate for preventing both diseases.
More Related Videos
11:21Forward Genetics Screens Using Macrophages to Identify Toxoplasma gondii Genes Important for Resistance to IFN-γ-Dependent Cell Autonomous Immunity
Published on: March 12, 2015
09:56Toxoplasma gondii Cyst Wall Formation in Activated Bone Marrow-derived Macrophages and Bradyzoite Conditions
Published on: August 12, 2010